Stockreport

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium [Yahoo! Finance]

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company's lead clinical asset, CUE-101, will be featured in a presentati [Read more]